Investigational drug · Phase 3
Buparlisib & Paclitaxel
Also called: AN2025
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head and Neck Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
9
Any phase or sponsor naming "Buparlisib & Paclitaxel"
First trial start
2020
Dec 12, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Buparlisib & Paclitaxel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Head and Neck Cancer
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Buparlisib & Paclitaxel" as an intervention, largest first.
- The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCCPivotal-lookingCompleted
Adlai Nortye Biopharma Co., Ltd.Industry
NCT04338399 · 487 participants · Start Dec 12, 2020 · Primary completion Nov 2, 2025
Drug: Buparlisib & Paclitaxel · For: Head and Neck Cancer
Sites: Duarte, California; New Haven, Connecticut; Tampa, Florida · 162 sites in all
- A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K ActivationPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01572727 · 416 participants · Start Aug 2012 · Primary completion Jun 2015
Drug: Paclitaxel; BKM120 matching placebo and 1 more · For: Breast Cancer
Sites: Chandler, Arizona; Phoenix, Arizona; Fayetteville, Arkansas · 112 sites in all
- Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum TherapyPivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT01852292 · 157 participants · Start Oct 1, 2013 · Primary completion Mar 30, 2017
Drug: Buparlisib; Buparlisib matching Placebo and 1 more · For: Head and Neck Squamous Cell Carcinoma
Sites: Fayetteville, Arkansas; Boston, Massachusetts; St Louis, Missouri · 58 sites in all
- A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without TrastuzumabCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01285466 · 110 participants · Start Jan 2011 · Primary completion Oct 2014
Drug: BEZ235 + paclitaxel; BKM120 + paclitaxel and 2 more · For: Metastatic or Locally Advanced Solid Tumors
Sites: Brussels, Belgium; Wilrijk, Belgium; Cologne, Germany · 10 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01816594 · 50 participants · Start Sep 3, 2013 · Primary completion Feb 18, 2015
Drug: BKM120; Trastuzumab and 2 more · For: HER2-positive Newly Diagnosed, Primary Breast Cancer
Sites: Parkville, Australia; Salzburg, Austria; Lübeck, Germany · 7 sites in all
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT01297452 · 45 participants · Start Feb 15, 2011 · Primary completion Mar 29, 2017
Drug: BKM120 days 1 - 21 plus paclitaxel + carboplatin; BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin and 2 more · For: Solid Tumors
Sites: New York, New York
Novartis PharmaceuticalsNovartis (NVS)
NCT01820325 · 6 participants · Start Sep 9, 2013 · Primary completion Jun 18, 2014
Drug: Buparlisib; Buparlisib placebo and 2 more · For: Non-Small Cell Lunch Cancer
Sites: Fayetteville, Arkansas; Portland, Oregon; Toronto, Canada · 7 sites in all
- Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian CancerWithdrawn
Rutgers, The State University of New JerseyAcademic, hospital or other
NCT02117817 · 0 participants · Start Feb 2015 · Primary completion Feb 25, 2015
Drug: BKM120; Nabpaclitaxel · For: Ovarian Cancer; Endometrial Cancer; Recurrent Ovarian Cancer and 1 more
Washington University School of MedicineAcademic, hospital or other
NCT01953445 · 0 participants · Start Aug 2014 · Primary completion Jun 2015
Drug: paclitaxel; BKM120 · For: Breast Neoplasms
Newest research
PubMed records naming it or its code names, newest first.
- Immune-checkpoint inhibitors versus other systemic therapies in advanced head and neck cancer: a network meta-analysis.
Tang L, Liu T, Chen J, et al. · Immunotherapy 2021
Also in development for Head and Neck Cancer
- APG-157Phase 33 trials
Aveta Biomics, Inc. · Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
- SurzebiclimabBGB-A425Phase 33 trials
BeOne Medicines (BeiGene) · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- EvorpaceptALX148Phase 25 trials
ALX Oncology Inc. · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Metastatic
- BT5528nuzefatide pevedotinPhase 23 trials
BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
- INCAGN02385Phase 23 trials
Incyte · Melanoma, Endometrial Cancer, Head and Neck Cancer
- INCAGN02390Phase 23 trials
Incyte · Melanoma, Endometrial Cancer, Head and Neck Cancer
- MCLA-129Phase 23 trials
Betta Pharmaceuticals Co., Ltd. · Non-Small Cell Lung Cancer, Solid Tumor, Head and Neck Cancer
- Carboplatin AUC-5Phase 22 trials
Inhibrx Biosciences, Inc · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.